A Phase 1 Clinical Trial of CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Exocrine Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2019
At a glance
- Drugs CEND-1 (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors DrugCendR
- 31 Jan 2019 Early data from the study, presented in a DrugCendR media release.
- 31 Jan 2019 According to a DrugCendR media release, the first Phase 2a type expansion cohort for early efficacy is now open. The study is expected to be fully enrolled with at least 30 patients in the second quarter of 2019.
- 26 Dec 2018 Planned End Date changed from 28 Feb 2020 to 30 Dec 2019.